Concepedia

Benjamin Bonavida

BB

250

Publications

14.6K

Citations

70

H-Index

1968

Active since

Affiliations

University of California, Los Angeles(Current)

UCLA Jonsson Comprehensive Cancer Center

Hospital Infantil de México Federico Gómez

Institute for Myeloma & Bone Cancer Research

Kyoto University

Benjamin Bonavida is an author at University of California, Los Angeles specializing in medicine, cell biology, and immunology.

ORCID

Top concepts

Publications per year

1968–2024

250

Publications

250

Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs

Aïcha Demidem, Tammy Lam, Steve Alas et al. · Cancer Biotherapy and Radiopharmaceuticals · 1997 · 397 citations

Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.

Steve Alas, Benjamin Bonavida · PubMed · 2001 · 295 citations

, , +18

Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.

Steve Alas, Christos Emmanouilides, Benjamin Bonavida · PubMed · 2001 · 281 citations

, , +15

Serum <scp>B</scp>‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

Eric Sanchez, Mingjie Li, Alex Kitto et al. · British Journal of Haematology · 2012 · 271 citations

Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.

Steve Alas, Benjamin Bonavida · PubMed · 2003 · 241 citations

, , +20

Rows per page

1–5 of 250